UroGen Pharma Ltd (URGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.28B
Last updated: Nov 17, 2026 at 6:00 PM ET
UroGen Pharma Ltd (URGN) Statistics
UroGen Pharma (URGN) has a market cap of $1.28B and an enterprise value of $1.39B. Revenue grew 159.29% over the last 12 months from the 12 months before. It kept -26.27% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 8.28% above the market cap, as debt exceeds cash.
| Market Cap | $1.28B |
|---|---|
| Enterprise Value | $1.39B |
| Latest price (Nov 17, 2026) | $29.87 |
Key Dates
The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 1, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 6.0x. Its year-end P/S ranged from 3.1x to 346.5x from 2017 to 2025.
| P/S Ratio | 6.0x |
|---|---|
| Forward P/S | 4.0x |
Price Statistics
The stock is up 25.72% over 52 weeks and trades 17.94% below its 50-day average.
| Beta (1Y) | 1.17 |
|---|---|
| 52-Week Change | +25.72% |
| 1-Month Change | -12.53% |
| 3-Month Change | -40.60% |
| 6-Month Change | +5.70% |
| 5-Year Change | +90.23% |
| Total Return (1Y) | +25.72% |
| Total Return (3Y CAGR) | +33.83% |
| Total Return (5Y CAGR) | +19.01% |
| Return vs SPY (1Y) | +15.28% |
| Max Drawdown (1Y) | -50.79% |
| Max Drawdown (3Y) | -79.67% |
| Sharpe Ratio (1Y) | 0.38 |
| Correlation with SPY (1Y) | 0.26 |
| 50-Day Average | $36.40 |
| 200-Day Average | $31.78 |
| 52-Week Range | $16.50 to $50.81 |
| RSI (14 Days) | 44.5 |
| Average Volume (20 Days) | 1.49M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.40x current liabilities.
| Current Ratio | 3.40x |
|---|---|
| Quick Ratio | 3.06x |
| Interest Coverage | -2.78x |
Returns and Efficiency
Return on invested capital is -73.72% over the last 12 months.
| Return on Assets (ROA) | -24.18% |
|---|---|
| Return on Invested Capital (ROIC) | -73.72% |
| Return on Capital Employed (ROCE) | -24.86% |
| ROA (5Y Average) | -70.36% |
| Asset Turnover | 1.10x |
| Inventory Turnover | 0.86x |
| Receivables Turnover | 2.43x |
| Cash Conversion Cycle | -164 days |
Scores
URGN has an Altman Z-Score of -1.75, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -1.75 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $250.25M over the last 12 months.
| Revenue | $250.25M |
|---|---|
| Revenue Growth (YoY) | +159.29% |
| Gross Profit | $228.75M |
| Operating Income | -$30.94M |
| Pretax Income | -$64.15M |
| Net Income | -$65.75M |
| EBIT | -$49.19M |
| Reported EPS (TTM) | -$1.31 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $85.56M |
|---|---|
| Total Debt | $191.94M |
| Net Debt | $106.37M |
| Net Debt Per Share | $2.10 |
| Working Capital | $177.87M |
| Shareholder Equity | -$125.22M |
| Total Assets | $271.87M |
| Total Liabilities | $397.09M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $203.00K of capital spending, operating cash flow left -$132.05M of free cash flow.
| Operating Cash Flow | -$131.85M |
|---|---|
| Capital Expenditures | $203.00K |
| Free Cash Flow | -$132.05M |
| FCF Per Share | -$2.70 |
| Depreciation and Amortization | $5.16M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -12.36%.
| Gross Margin | 91.41% |
|---|---|
| Operating Margin | -12.36% |
| Pretax Margin | -25.64% |
| Net Margin | -26.27% |
| EBIT Margin | -19.66% |
| FCF Margin | -52.77% |
| Gross Margin (5Y Average) | 88.98% |
Growth
Revenue grew 19.49% a year over 3 years.
| Revenue Growth (3Y CAGR) | +19.49% |
|---|---|
| Revenue Growth (5Y CAGR) | +56.22% |
Dividends and Yields
URGN does not pay a dividend. Its free cash flow yield is -8.74%.
| FCF Yield | -8.74% |
|---|---|
| Buyback Yield | -2.11% |
| Shareholder Yield | -2.11% |
Peer Position
Against 10 similar companies, URGN has the 6th highest P/S.
P/S RatioPeer median 4.7x
ROICPeer median -7.40%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +24.54%
| P/S Ratio | 6.0x vs 4.7x median |
|---|---|
| ROIC | -73.72% vs -7.40% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +159.29% vs +24.54% median |
Analyst Forecast
Consensus estimates put revenue growth at 120.71% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +120.71% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About URGN
What is URGN's market cap?
UroGen Pharma has a market cap of $1.28B. Its enterprise value, which adds debt and subtracts cash, is $1.39B.
How many shares of URGN are outstanding?
UroGen Pharma has 50.56M shares outstanding. The count is up 5.20% from a year earlier.
Does URGN pay a dividend?
No. UroGen Pharma does not pay a dividend.
How much debt does URGN have?
UroGen Pharma has $191.94M of total debt and $85.56M of cash and equivalents, a net debt position of $106.37M.
URGN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors, Government Contracts